

April 22, 2025



NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Additional Presentations Demonstrate Ongoing Commitment to Research & Innovation in Precision Oncology

FORT MYERS, Fla.--(BUSINESS WIRE)-- **NeoGenomics, Inc.** (“**NeoGenomics**” or the “**Company**”) (**NASDAQ:NEO**), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling. The validation study, along with five additional abstracts, will be presented at the [American Association for Cancer Research® \(AACR\) Annual Meeting 2025](#) in Chicago, April 25–30.

PanTracer LBx is a blood-based test that analyzes circulating tumor DNA to identify key genomic alterations in patients with advanced-stage solid tumors. It is designed to support treatment decisions when tumor tissue is unavailable or insufficient—a common challenge in oncology care. In the validation study, PanTracer LBx demonstrated high performance in identifying key biomarkers—including MSI (microsatellite instability) and TMB (tumor mutational burden)—across multiple cancer types, reinforcing its potential to guide therapy selection and expand access to precision oncology. The poster, “[Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay](#),” will be presented on Tuesday, April 29, from 9 AM - 12 PM CT, Section 10, Poster 27.

NeoGenomics has also launched an Evaluation Assessment Program for PanTracer LBx, allowing select physicians to use the assay ahead of full commercial availability. The program is intended to identify opportunities to streamline logistics, reporting, and customer support.

“The clinical validation of PanTracer LBx is the result of extensive analytical testing and represents a meaningful addition to our specialized testing menu designed to serve our community oncologists,” said Andrew A. Lukowiak, Ph.D., Chief Innovation Officer at NeoGenomics. “Our presence at AACR reflects a deep commitment to advancing the accessibility of cutting-edge oncology diagnostics and developing practical, real-world solutions that support patients and providers alike.”

The company will present five additional posters that span topics such as spatial profiling, tumor biology, and genomic co-occurrence, including:

- [Characterization of GM-CSF and G-CSF expressing cell subtypes in the tumor microenvironment using the Integrated MultiOmyx-RNAscope assay](#)
 - April 28, 2:00 PM - 5:00 PM, Section 7, Poster 30
- [Accurate, high-throughput spatial profiling of whole slide samples with the NeoLYTX](#)

pipeline

- April 28, 9:00 AM - 12:00 PM, Section 46, Poster 29
- High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection
 - April 28, 9:00 AM - 12:00 PM, Section 1, Poster 14
- Co-occurrence of gene fusions with SNV/Indels and with CNVs on solid tumors in a cohort of 795 patients from the community setting
 - April 28, 2:00 PM - 5:00 PM, Section 31, Poster 27
- Comprehensive characterization of renal cell carcinomas identifies metabolic reprogramming of the tumor microenvironment associated with disease progression
 - April 29, 2:00 PM - 5:00 PM, Section 12, Poster 10

NeoGenomics will also showcase its oncology diagnostics solutions at booth #2449.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document

(unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250422684655/en/>

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.